FiercePharma

The biopharmaceutical industry is rapidly evolving, bringing fresh concepts to light every day. Subscribers turn to FiercePharma as their essential resource for the most current news, insights, and data regarding medications and the companies behind them. Each business day, FiercePharma and its associated publications provide comprehensive coverage of the pharmaceutical sector, spanning from late-stage drug development to all stages of the product lifecycle. Stay informed about topics such as regulatory approvals, negotiations with payers, manufacturing processes, marketing strategies, patent disputes, government inquiries and regulations, mergers and acquisitions, and much more.

International, Trade/B2B

English

Newsletter (Digital)

Outlet metrics

Domain Authority

Ranking

Global

#97238

United States

#28888

Health/Health

#680

Traffic sources

Monthly visitors

Articles

Meribel debuts as CDMO after Recipharm, Synerlab acquisitions in Europe

3 days ago | fiercepharma.com | Joseph Keenan

For a second time in less than a month, a new CDMO has uncloaked. This time, Meribel Pharma Solutions is gracing the stage after its financial backer snapped up a string of production facilities from Recipharm and acquired the French contract manufacturer Synerlab. Meribel, which will be based in the United Kingdom, is positioning itself as a mid-sized CDMO with a "strong legacy of expertise" in oral solid, semi-solid and sterile drugs, the company said in an April 15 press release.
Navigating Trump’s tariffs for pharma

6 days ago | fiercepharma.com | Ayla Ellison |Fraiser Kansteiner

After a batch of much-anticipated reciprocal tariffs spared pharmaceuticals in early April, drugmakers, medtech companies, manufacturers and other outfits across the life sciences spectrum are still scrambling to respond to mounting trade pressures. While many unknowns remain, biopharma companies should waste no time in starting to evaluate their options.
Fierce Pharma Asia—The latest on Trump's tariffs; Leqembi's EU approval; Kyowa Kirin's biologics plant

6 days ago | fiercepharma.com | Angus Liu

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. The European Commission has approved Eisai and Biogen's Leqembi in Alzheimer's disease. Kyowa Kirin has finished the build-out of a Japanese biologics plant. And more. 1.
GSK kicks off Blenrep's market return with first myeloma combo nod in UK

1 week ago | fiercepharma.com | Angus Liu

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has become the first to sign off on Blenrep as part of two different combinations for treating multiple myeloma patients who have received at least one prior therapy, GSK said Thursday.
TV drug ad spending continues upward climb, logging nearly 30% growth in Q1

1 week ago | fiercepharma.com | Andrea Park

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV commercials in the first quarter compared to the same period a year ago. Across the first three months of this year, according to iSpot.TV, drugmakers have spent a combined $729.4 million to air commercials for the top 10 brands, up from $567.3 million in the first quarter of 2024.
Moderna advances pandemic preparedness agenda with UK clearance for commercial mRNA vaccine plant

1 week ago | fiercepharma.com | Joseph Keenan

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key regulatory hurdle at its flagship production plant in the United Kingdom. The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Moderna a manufacturer and importer's license at its vaccine facility in Harwell, Oxfordshire.
With looming Trump tariffs, pharma companies demand changes to stay in EU

1 week ago | fiercepharma.com | Angus Liu

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. In a letter sent to European Commission President Ursula von der Leyen, 32 pharma companies demanded more favorable policies for them to maintain operations in the EU amid looming U.S. tariffs, French newspaper Les Echos reported.
GSK scolded after complainant flags ‘shocking error’ in prescribing information

1 week ago | fiercepharma.com | Nick Paul Taylor

GSK has been found guilty of bringing discredit on the pharma industry after a complainant flagged “a shocking error” in the prescribing information for the JAK inhibitor Omjjara. A person who self-identified as a health professional wrote to the PMCPA, the body that oversees the U.K. marketing code, after finding fault with prescribing information for Omjjara.
Bluebird, after exploring 2nd buyout offer, sticks with Carlyle and SK Capital deal

1 week ago | fiercepharma.com | Eric Sagonowsky

After exploring a rival buyout offer worth 50% more than its first, bluebird bio is back where it started. Wednesday, the company said that it's sticking with the decision to sell to private equity firms Carlyle and SK Capital for $3 per share, plus a contingent payment of $6.84 per share if it meets a future net sales threshold.
Apellis, AstraZeneca break down their #FierceMadness 2025 Drug Ad Tournament success

1 week ago | fiercepharma.com | Andrea Park

After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the final round of the annual #FierceMadness bracket competition. The trophy ultimately went to Apellis, but both companies’ commercials racked up plenty of fans on the road to their championship match-up.